ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Dermatitis
Atopic Dermatitis
Skin Diseases
Dyssomnias
Food Hypersensitivity
Hypersensitivity
Parasomnias

Eczema trials near Berlin, BE, DEU:

Topical Ruxolitinib Evaluation in Chronic Hand Eczema

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema...

Active, not recruiting
Hand Eczema
Drug: Ruxolitinib cream
Drug: Vehicle

Phase 2

Incyte
Incyte

Mahlow, Germany and 35 other locations

The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adu...

Enrolling
Eczema
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Almirall
Almirall

Berlin, Germany and 32 other locations

The purpose of this study is to assess the safety, tolerability, drug levels, drug effects, and impact on disease severity of BMS-986326 in participa...

Enrolling
Dermatitis, Atopic
Other: Placebo
Drug: BMS-986326

Phase 1

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Berlin, BE, Germany and 10 other locations

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or a...

Enrolling
Atopic Dermatitis
Drug: Ruxolitinib Cream
Drug: Vehicle Cream

Phase 3

Incyte
Incyte

Berlin, Germany and 104 other locations

Global Assessment for Atopic Dermatitis (vIGA-AD).* Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Eczema...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

Phase 3

Amgen
Amgen

Berlin, Germany and 196 other locations

The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have...

Not yet enrolling
Dermatitis, Atopic
Drug: GSK1070806

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Berlin, Germany and 90 other locations

Locations recently updated

This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK10...

Enrolling
Dermatitis, Atopic
Drug: GSK1070806
Drug: Placebo

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Berlin, Germany and 92 other locations

The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB9741 administered by intravenous infusion or s...

Active, not recruiting
Atopic Dermatitis
Drug: UCB9741
Drug: Subcutaneous Placebo

Phase 1

UCB
UCB

Berlin, Germany and 9 other locations

Locations recently updated

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Berlin, Germany and 557 other locations

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Phase 3

Lilly
Lilly

Berlin, Germany and 320 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems